Follow the Money The Outlook for Outsourced Spending on Early Development Services

Pune India - February 14, 2017 /MarketersMEDIA/ —

PharmSource - Follow the Money: The Outlook for Outsourced Spending on Early Development Services According to this latest report, PharmSource - Follow the Money: The Outlook for Outsourced Spending on Early Development Services", the driver of this early development activity has been the huge level of external funding flowing into emerging bio/pharma companies from venture capitalists and public markets. However, external funding for bio/pharma has always been a boom or bust” proposition, and the likelihood that funding will be cut drastically always lurks on the horizon. This makes it difficult for CDMOs and CROs to pull the trigger on investments in new capacity..

Complete report on PharmSource - Follow the Money: The Outlook for Outsourced Spending on Early Development Services spread across 107 pages is available at http://www.reportsnreports.com/contacts/discount.aspx?name=855359

Demand for development services to support Phase 1 and Phase 2 clinical trials is driving double-digit growth for CROs and CDMOs. Demand for clinical manufacturing services is actually outstripping industry capacity and leading to delays in getting clinical trial materials needed for studies.
List Of Table:
• Breakdown of Phase I and Phase II Trials by Primary Sponsor, H1 2012-H1 2016
• Figure 2 Operating Expenditure of US Emerging Biopharma Companies Pre- and Post-IPO
• Figure 3 Operating Expenditure of US Emerging Biopharma Companies Pre- and Post-SPO
• Figure 4 Estimated Cost of Getting Candidates Through Clinical Trial Phases
• Figure 5 Ownership of Emerging Bio/Pharma Companies Sponsoring Clinical Trials H1 2016
• Figure 6 Equity Funding to Emerging Bio/Pharma 2010-2016
• Figure 7 Venture Capital Investment in Bio/Pharma Companies
• Figure 8 VC Funding to Emerging Bio/Pharma 2010-2015
• Figure 9 NASDAQ Biotech Index January 13-December 2016
• Figure 10 R&D Spend and Cash Runway for US Emerging Bio/Pharma Companies
• Figure 11 Revenue as a Funding Source for US Emerging BioPharma
• Figure 12 Proportion of Companies with > 2 Years Cash or Increasing Cash Reserves

Request Sample
http://www.reportsnreports.com/contacts/requestsample.aspx?name=855359

Key Highlights
• Follow the Money: The Outlook for Outsourced Spending on Early Development Services exams the link between external funding sources and early drug development, and addresses the outlook for continued funding over the next two years.

Get this Report: http://www.reportsnreports.com/purchase.aspx?name=855359

Reasons to Buy
This report provides important insight that you won’t find in any other source. This report is required reading for -
• CDMOs and CROs: market trends, capital investment decision-making, strategic planning, performance benchmarking
• Bio/pharma: supplier performance benchmarking, market trends, competitive intelligence
• Private equity: investment targeting, portfolio company performance benchmarking

About Us:
Reportsnreports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Contact Info:
Name: Ritesh Tiwari
Email: Send Email
Organization: ReportsandReports
Address: Pune
Phone: + 1 888 391 5441
Website: http://www.reportsnreports.com/reports/855359-pharmsource-follow-the-money-the-outlook-for-outsourced-spending-on-early-development-services.html

Release ID: 169370